About Uluru (OTCMKTS:ULUR)
ULURU Inc. is a specialty pharmaceutical company focused on developing and commercializing a range of wound care and muco-adhesive film products based on its Nanoflex and OraDisc technologies for patients, healthcare professionals and healthcare payers. The Company operates through the research, development and commercialization of pharmaceutical products segment. Utilizing its technologies, three of its products have been approved for marketing in various global markets. Altrazeal Transforming Powder Dressing is based on its Nanoflex technology, which changes the way healthcare providers approach their treatment of wounds. The product is indicated for both exuding acute wounds, such as donor sites, non-healing surgical wounds, and trauma and for chronic wounds, such as venous leg ulcers, diabetic foot ulcers and pressure ulcers. Aphthasol is a drug approved for the treatment of canker sores. OraDisc is developed as an improved drug delivery system for the treatment of canker sores.
Industry, Sector and Symbol
Trailing P/E Ratio-0.583333333333333
Forward P/E RatioN/A
Sales & Book Value
Price / Sales16.02
Price / CashN/A
Book Value$0.02 per share
Price / Book1.75
Return on Equity-31.89%
Return on Assets-22.00%
Uluru (OTCMKTS:ULUR) Frequently Asked Questions
What is Uluru's stock symbol?
Uluru trades on the OTCMKTS under the ticker symbol "ULUR."
How were Uluru's earnings last quarter?
Uluru Inc (OTCMKTS:ULUR) issued its earnings results on Monday, November, 17th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.02. The specialty pharmaceutical company earned $0.32 million during the quarter, compared to analysts' expectations of $0.70 million. Uluru had a negative return on equity of 31.89% and a negative net margin of 267.87%. During the same period in the prior year, the company earned ($0.05) EPS. View Uluru's Earnings History.
When will Uluru make its next earnings announcement?
Who are some of Uluru's key competitors?
Some companies that are related to Uluru include Critical Outcome T (COTQF), Bioblast Pharma (ORPN), Callitas Health In (MPHMF), Sunshine Heart (CHFS), ESSA Pharma (EPIX), Strata Skin Sciences (SSKN), Secure Point Technologies (IMSC), Neurometrix (NURO), Mateon Therapeutics (MATN), Rosetta Genomics (ROSG), Lombard Medical (EVARF), Dextera Surgical (DXTR), TearLab (TEAR), Delcath Systems (DCTHD), Affymax (AFFY), BG Medicine (BGMD), Tetralogic Pharmaceuticals (TLOG) and Imris (IMRSQ).
Who are Uluru's key executives?
Uluru's management team includes the folowing people:
- Bradley J. Sacks, Chairman of the Board
- Vaidehi Shah, Chief Executive Officer, Director
- Terrance K. Wallberg, Chief Financial Officer, Vice President, Treasurer, Secretary, Director
- Arindam Bose, Director
How do I buy Uluru stock?
Shares of Uluru can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uluru's stock price today?
One share of Uluru stock can currently be purchased for approximately $0.04.
How big of a company is Uluru?
Uluru has a market capitalization of $6.64 million and generates $440,000.00 in revenue each year. The specialty pharmaceutical company earns $-4,450,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis. Uluru employs 2 workers across the globe.
How can I contact Uluru?
Uluru's mailing address is 4452 BELTWAY DRIVE, ADDISON TX, 75001. The specialty pharmaceutical company can be reached via phone at 214-905-5145.
MarketBeat Community Rating for Uluru (ULUR)MarketBeat's community ratings are surveys of what our community members think about Uluru and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Uluru (OTCMKTS:ULUR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Uluru (OTCMKTS:ULUR) Earnings History and Estimates Chart
Uluru (OTCMKTS ULUR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/16/2018|| || || || || || || || |
|4/1/2015||$0.01||$0.45 million||$0.23 million||View||N/A|
|11/17/2014||Q3 14||($0.01)||($0.03)||$0.70 million||$0.32 million||View||N/A|
|8/15/2014||($0.02)||($0.03)||$0.43 million||$0.21 million||View||N/A|
|4/1/2014||Q4 13||($0.04)||$0.14 million||$0.13 million||View||N/A|
|8/15/2013||Q2 2013||($0.06)||$0.06 million||$0.03 million||View||N/A|
Uluru (OTCMKTS:ULUR) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Uluru (OTCMKTS:ULUR)
No dividend announcements for this company have been tracked by MarketBeat.com
Uluru (OTCMKTS ULUR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.90%
Institutional Ownership Percentage: 0.01%
Uluru (OTCMKTS ULUR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/29/2016||Bradley J Sacks||Insider||Buy||266,480||$0.07||$18,653.60|| |
|3/29/2016||Terrance K Wallberg||CFO||Buy||701,262||$0.07||$49,088.34||825,519|| |
|1/6/2014||Gmbh Ipmd||Major Shareholder||Buy||1,250,000||$0.40||$500,000.00|| |
|10/24/2013||Gmbh Ipmd||Major Shareholder||Buy||750,000||$0.40||$300,000.00|| |
|9/6/2013||Gmbh Ipmd||Major Shareholder||Buy||750,000||$0.40||$300,000.00|| |
|5/7/2013||Gmbh Ipmd||Major Shareholder||Buy||1,250,000||$0.40||$500,000.00|| |
|3/14/2013||Kerry P Gray||CEO||Buy||1,000,000||$0.40||$400,000.00|| |
|3/14/2013||Terrance K Wallberg||CFO||Buy||100,000||$0.40||$40,000.00|| |
Uluru (OTCMKTS ULUR) News Headlines
Uluru (OTCMKTS:ULUR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Uluru (OTCMKTS ULUR) Stock Chart for Tuesday, January, 23, 2018